SharePoint
Aide
Faire avancer la sûreté nucléaire

La Recherchev2

Publications

Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment


Fermer

Authentification

Email :

Mot de passe :

Bensidhoum M, Chapel A, François S, Demarquay C, Mazurier C, Fouillard L, Bouchet S, Bertho JM, Gourmelon P, Aigueperse J, Charbord P, Gorin NC, Thierry D, Lopez M.
Blood - Volume 103, Issue 9, 1 May 2004, Pages 3313-3319

Type de document > *Article de revue

Mots clés > radioprotection

Unité de recherche > IRSN/DRPH/SRBE/LTCRA

Auteurs > AIGUEPERSE Jocelyne, BERTHO Jean-Marc, CHAPEL Alain, DEMARQUAY Christelle, FRANCOIS Agnès, GOURMELON Patrick, THIERRY Dominique

Date de publication > 01/05/2004

Résumé

The Stro-1 antigen potentially defines a mesenchymal stem cell (MSC) progenitor subset. We here report on the role of human ex vivo-expanded selected Stro-1+ or Stro-1- MSC subsets on the engraftment of human CD34+ cord blood cells in the nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse model. The data show that cotransplantation of expanded Stro-1- cells with CD34 + cells resulted in a significant increase of human CD45, CD34, CD19, and CD11b cells detected in blood or in bone marrow (BM) and spleen as compared with the infusion of CD34+ cells alone. Infusion into mice of expanded Stro-1+ and Stro-1- cells (without CD34 + cells) showed that the numbers of Stro-1+-derived (as assessed by DNA analysis of human ß-globin with quantitative polymerase chain reaction [PCR]) were higher than Stro-1- derived cells in spleen, muscles, BM, and kidneys, while more Stro-1--derived than Stro-1+-derived cells were found in lungs. The transduction of expanded Stro-1+ cells with an enhanced green fluorescent protein (eGFP) gene did not modify their cytokine release and their homing in NOD/ SCID mouse tissues. The difference between the hematopoietic support and the homing capabilities of expanded Stro-1+ and Stro-1- cells may be of importance for clinical therapeutic applications: Stro-1+ cells may rather be used for gene delivery in tissues while Stro-1- cells may rather be used to support hematopoietic engraftment. © 2004 by The American Society of Hematology.